Heffernan Acquires Shares in enGene Therapeutics

Michael Heffernan purchased 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN) on June 16, 2026. This insider transaction did not disclose a price or total value, but it reflects a notable insider interest in the company.

Insider Buying and Selling at enGene Therapeutics Inc.

On June 16, 2026, several insiders at enGene Therapeutics were active in buying shares. Gerald Brunk, Richard Glickman, Wouter Joustra, Lota Zoth, and Paul Hastings each acquired 31,000 shares, while William Grossman, the Interim Chief Medical Officer, purchased 231,000 shares. None of these transactions were part of a pre-planned trading program.

Other Institutional Activity in enGene Therapeutics

In the institutional space, FCPM III Services B.V. maintained its position in enGene with 9,632,561 shares valued at approximately $65.6 million. Perceptive Advisors LLC reduced its holdings by 41,570 shares, ending with 5,827,506 shares worth about $39.7 million. Siren, L.L.C. increased its stake significantly by 1,916,895 shares, bringing its total to 5,253,159 shares valued at $35.8 million. Blue Owl Capital Holdings LP also added 1,055,416 shares, resulting in a total of 4,416,353 shares worth around $30.1 million.

enGene Therapeutics Stock Snapshot

Shares of enGene Therapeutics Inc. (NasdaqCM:ENGN) traded near $1.75. The company has a market capitalization of approximately $117.2 million. It has no meaningful forward P/E ratio due to its unprofitability. The stock's 52-week range is between $1.40 and $12.25, with a 50-day moving average of $4.33 and a 200-day moving average of $7.13. enGene has a robust current ratio of 12.57 and a quick ratio of 12.07, indicating strong liquidity, but a debt-to-equity ratio of 13.07.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright & Co. maintained its 'buy' rating on enGene Therapeutics with a price target of $4.00. UBS maintained a 'hold' rating with a $2.00 target on May 14, 2026. Wells Fargo downgraded the stock to 'hold' with a $2.00 target on May 8, 2026. The consensus price target among analysts is about $3.57, with seven analysts offering opinions.

About enGene Therapeutics

enGene Therapeutics Inc. is a biotechnology company based in Montreal, Canada. It focuses on developing genetic medicines for bladder cancer patients. Its leading product, detalimogene voraplasmid, is a monotherapy aimed at treating non-muscle invasive bladder cancer. The company is also advancing its LEGEND program, currently in Phase 2 trials. enGene is led by CEO Ronald H. W. Cooper and employs 81 people.

Bottom Line

Michael Heffernan's purchase of 31,000 shares in enGene Therapeutics highlights insider confidence in the company's potential. enGene, a clinical-stage biotech firm, is navigating the competitive healthcare sector with its innovative treatments. While the stock currently trades at a modest $1.75, analysts maintain varied outlooks, reflecting the complexities of its market position.